APLS vs PAYC · rev $781.4M vs P/E 33, rev $1.10B
Apellis Pharmaceuticals Inc (APLS) versus Paycom Soft (PAYC) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Paycom Soft (PAYC) is a software - application company listed on US.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
Latest reported PAYC revenue for 2026-06-30 was $1.10B. Net income was $263.1M. Revenue was up 92.9% from 2026-03-31 to 2026-06-30. PAYC currently screens at market cap $13.06B and trailing P/E 33.1.
APLS currently screens at market cap $2.29B. PAYC currently screens at market cap $13.06B and trailing P/E 33.1.
Not investment advice. Open the APLS and PAYC stock pages for the full models.
Not investment advice.